The Pharmaceutical Supply Chain Is Ready For Blockchain

Coin Revolution | October 14, 2019

In pharmaceuticals and the life sciences sector, the most valuable commodity is trust. When a patient pops a pill, he is putting his life on the hands of the prescribing doctor and the drug company that developed the pill alongside the supply chain that delivered it to him. Now in drug production and supply, these problems are thankfully rare. Although the consequences of failure could be more significant for the pharmaceutical company in terms of reputation, you can only trust that the supply chain is always watertight, which hasn’t always been the case. Earlier in the summer, there were reports of a criminal gang in Italy stealing unsafe medicine and selling them in UK pharmacies. Although the drugs were not counterfeit, they had been outside the regulated supply chain for long and had been classified as falsified. The industry is well aware of its responsibilities to patients and is quick to take steps to address the existing issues that put people’s safety at risk. For instance the Chicago Tylenol murders back in 1980, which provides a good example. The industry was quick enough to develop tamper-resistant packaging, although Johnson & Johnson ought to be commended for how they handled the crisis.

Spotlight

The Full Electric PH-Line is designed for the production of containers for the Pharmaceutical sector. Configurable in aseptic or Ultraclean blowing system.

Spotlight

The Full Electric PH-Line is designed for the production of containers for the Pharmaceutical sector. Configurable in aseptic or Ultraclean blowing system.

Related News

KYAN Therapeutics Exclusively Licenses Small Molecule HDAC Inhibitors for AI-Powered Cancer Drug Development

KYAN Therapeutics, Inc. | September 24, 2020

KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate Cancer. The low toxicity and metabolic stability of KYAN-001 indicates a better safety and tolerability profile than FDA approved pan-HDAC inhibitors which suffer from toxicity issues and side effects. KYAN-001 also uniquely inhibits HDAC4 nucleoshuttling to further drive its anti-cancer effects.

Read More

PHARMACY MARKET

Yangtze River Pharmaceutical Group Selects TraceLink Platform for Global Compliance

Yangtze River Pharmaceutical, TraceLink | May 06, 2021

TraceLink Inc., the leading digital network platform company, today announced that Yangtze River Pharmaceutical Group has selected TraceLink's global compliance solution to aid its plans for global growth. As the company gears up for international market expansion this year, Yangtze River Pharmaceutical Group (YRPG) will use TraceLink's multienterprise compliance applications and industry-leading digital supply network to comply with track and trace requirements in multiple markets, including the United States and Europe. "As we approach our 50th anniversary this year, we are preparing to deliver our innovations to global markets beyond China," said Mr. Luo Bai Gui GM's Executive Assistant, International Projects from YRPG. "Given the broad scope of our portfolio and diverse business model, TraceLink' s integrated network, global compliance solutions and low total cost of ownership are crucial for us to achieve commercial success in multiple markets." "Global commercialization has become a top priority during this special milestone year for YRPG and serialization compliance is a necessary step in their preparation for global expansion," said Shabbir Dahod, President and CEO, TraceLink. "As one of the top pharmaceutical enterprises in China, YRPG is highly esteemed for its relentless innovation and TraceLink is proud to be their serialization partner of record as they embark on their journey of continued global growth." With more than 16,000 employees and over 20 subsidiaries located across China, YRPG has established R&D and production bases for innovative chemical medicines, patent traditional Chinese Medicine (TCMs) and biological medicines. Yangtze River Pharmaceutical Group's products include Chinese, Western medicines and APIs, covering ten fields, nearly 20 dosage forms and over 300 types of medicines and strengths. Nearly 100 innovative drugs for major diseases are currently under research & development. About Yangtze River Pharmaceutical Group With a total manufacturing footprint of more than 3 million square meters, Yangtze River Pharmaceutical Group employs 16,000 and owns 11 manufacturing subsidiaries located in Beijing, Shanghai, Nanjing, Guangzhou, etc. The company fields established R&D and production bases for innovative chemical medicines, patent traditional Chinese Medicine (TCM) and biological medicines. Currently, Yangtze River Pharmaceutical Group exports part of its portfolio assortment to 30 countries including Europe, Asia and Africa. About TraceLink TraceLink is the only business network creation platform for building integrated business ecosystems with multienterprise applications. Business networks are the foundation of an Industry 4.0 digitalization strategy that delivers customer-centric agility and resiliency of the end-to-end supply network leveraging the collective intelligence of an industry. TraceLink's Opus Digital Network Platform enables speed of open innovation and implementation with a partner ecosystem for no-code and low-code development of solutions and applications.

Read More

Intec Pharma Announces New Research Collaboration Agreement with MSD

Intec Pharma | October 08, 2020

Intec Pharma Ltd. ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Details of the agreement are confidential. "We are very excited to continue to work with MSD," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "This new agreement builds upon the relationship we have enjoyed in prior research and allows the companies to leverage their combined experience in delivery."

Read More